Teufel, Michael
Boehringer Ingelheim (United States)
2 papers on CoChatORCID 0009-0000-0238-9169
Most cited papers
- Verified
The MDM2-p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study
LoRusso, P., Yamamoto, N., Patel, M. R., Laurie, S. A., Bauer, T. M., Geng, J., Davenport, T., Teufel, M., Li, J., Lahmar, M., et al. (2023) · Cancer Discovery
Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer
Cited by 101
- Verified
A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM)
Sarkaria, J. N., Mrugala, M. M., Jaeckle, K. A., Burns, T. C., Vaubel, R. A., Parney, I. F., Chaichana, K., Clement, P. M., Martinez-Garcia, M., Sepulveda Sanchez, J. M., et al. (2024) · Journal of Clinical Oncology
Glioma Diagnosis and TreatmentCancer-related Molecular Pathways
Cited by 3
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free